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MAS-ALiterature on the relationship of cannabis use and cognition in schizophrenia provides the paradoxical view
that cannabis use is sometimes linked with less severe impairment in neurocognition. This paper explored
the possibility that this is a reﬂection of a dose related response between lifetime cannabis use and two
forms of cognition, neurocognition and metacognition, in schizophrenia. It was hypothesized that three
groups of patients could be differentiated, those with (1) little to no cannabis use with poor levels of cog-
nition, (2) moderate cannabis use and relatively better levels of cognition and (3) high cannabis use with
relatively poorer levels of cognition. Sixty-six adults with schizophrenia completed assessments of
neurocognition, metacognition and months of lifetime cannabis use. A k-means cluster analysis yielded
three distinct groups based on these assessments. The clusters included: (1) low cannabis/poor cognition
(n=34); (2) heavy cannabis/moderately impaired cognition (n=10); and (3) moderate cannabis/higher
cognition (n=22). Consistent with our hypothesis, participants with high andmoderate lifetime cannabis
use had lesser impairment of neurocognition and metacognition compared to low lifetime cannabis use.
Participants with moderate lifetime cannabis use also had lesser impairment of metacognition compared
to low and heavy use. These ﬁndings suggest that a dose related relationship exists between cannabis
use and cognition. Results could be due to an inﬂuence of pre-existing cognitive level on likelihood of life-
time cannabis use, or to an interaction between use and cognitive function.ter, Day Hospital 116H, 1481© 2016 Published by Elsevier Inc.1. Introduction
Cannabis use is a common comorbidity with schizophrenia
(Kavanagh et al., 2002; Nesvåg et al., 2015), with approximately
64.4% of individuals with schizophrenia reporting lifetime use
(Barnes et al., 2006) and 16% and 27%meeting the criteria for current
and lifetime cannabis use disorder (Koskinen et al., 2010). Cannabis
use has been associated with an earlier onset of schizophrenia
(Galvez-Buccollini et al., 2012; Veen et al., 2004). Further, individuals
who continue to use cannabis after their ﬁrst episode of psychosis
have a worse prognosis, with increased relapse and hospitalizations
(Alvarez-Jimenez et al., 2012), even when controlling for other
substances (Foti et al., 2010). Additionally, acute intoxication fromΔ-9-tetrahydrocannabinol (Δ-9-THC), the psychoactive component
in cannabis, has been shown to exacerbate psychotic symptoms in
schizophrenia (D'Souza et al., 2005).
While cannabis use may exacerbate symptoms of schizophrenia,
its impact on neurocognition, the most prominent form of cognition,
is less clear. In particular, studies on the relationship of cannabis use
and cognition in persons with schizophrenia present a paradox. On
one hand, cannabis seems to negatively affect cognition in persons
without schizophrenia. For example, acute, dose-related cognitive
impairments have been observed in healthy individuals with canna-
bis (Pope et al., 1996; 2001; Bolla et al., 2002; Lundqvist, 2005;
Solowij & Battisti, 2008; Crean, Crane & Mason, 2011), its psychoac-
tive constituent Δ-9-THC (D'Souza et al., 2004; Ranganathan and
D’souza 2006; Morrison et al., 2009), and synthetic cannabinoids
(Gunderson et al., 2012). Additionally, cannabis use has been associ-
ated with long-term cognitive decline in healthy individuals (Fried
et al., 2002; Meier et al., 2012). In schizophrenia, acute Δ-9-THC IV
16 A.M. Schnakenberg Martin et al. / Schizophrenia Research: Cognition 6 (2016) 15–21administration has also shown intensiﬁed cognitive dysfunction, as
indexed by greater cognitive impairment in learning and memory
(D'Souza et al., 2005). Additionally, schizophrenia patients displayed
greater sensitivity to these cognitive impairments from Δ-9-THC
compared to healthy controls.
On the other hand, lifetime cannabis use has been associatedwith
less severe neurocognitive impairment in schizophrenia (de la Serna
et al., 2010; Hanna et al., 2016; Jockers-Scherübl et al., 2007; Schnell
et al., 2009; Yücel et al., 2012). Speciﬁcally, these studies suggest that
persistent cannabis use prior to the age of 17 years old and before the
onset of psychotic symptoms is associated with elevated cognitive
performance compared to non-cannabis using peers. However,
other studies have failed to ﬁnd an association between cannabis
use and elevated cognitive performance (Cleghorn et al., 1991;
Pencer and Addington, 2003).
One possible explanation for this paradox is thatmoderate canna-
bis usemodulates a pathway to psychosiswhich is distinct fromother
pathways in that it does not affect neurocognition at the trait level. In
other words, perhaps moderate cannabis use increases risk for psy-
chosis without concurrent neurocognitive deﬁcits and hence those
individuals appear to be more neurocognitively intact. Alternatively,
theremay be other personswho are heavy cannabis userswhodevel-
op cognitive deﬁcits similar to the deﬁcits found in heavy using
healthy controls. This would suggest a model in which there are at
least three groups of persons including those with little to no canna-
bis use with poor levels of cognition, moderate cannabis use and rel-
atively better levels of cognition and high cannabis usewith relatively
poorer levels of cognition. Support for this model (Fig. 1) comes from
three primary ﬁndings in the literature. Firstly, there appears to be a
consistent dose-dependent relationship between lifetime cannabis
exposure and the later development of psychosis (Andréasson et al.,
1987; Gage et al., 2016; Henquet et al., 2005a; Van Os et al., 2002;
Zammit et al., 2002). Secondly, the cannabinoid system has been im-
plicated in the potential disruption of cognitive processes observed in
schizophrenia (Volk and Lewis, 2016). Finally, recent evidence sug-
gests that peoplewith schizophreniawith lifetime cannabis use dem-
onstrate less cognitive impairments, compared to non-using peers
(de la Serna et al., 2010; Hanna et al., 2016; Jockers-Scherübl et al.,
2007; Schnell et al., 2009; Yücel et al., 2012). Important to note,
these pathways are in regard to lifetime cannabis use, while acute
and residual cannabis use would be anticipated to have differential
effects on cognition and potentially psychotomimetic effects.
To test this possibility the current study sought to determine
whether cluster analyseswould differentiate three groups of patients
with schizophrenia on the basis of lifetime cannabis use and
neurocognition. We also included another form of cognition, meta-
cognition, in our cluster analysis. While the relationship between
metacognition, cannabis use and schizophrenia has not been exten-
sively studied, metacognition appears to be an intuitively important
domain of cognition that has potential impact on one's ability to
achieve recovery. As neurocognition directly refers more to rawFig. 1. Hypothetical paths to psychosis with lifetimeability to focus, remember and process information, metacognition
encompasses the speciﬁc ability to think about one's self, others and
the ability to use this knowledge. Originally used in the education lit-
erature to describe an individual's awareness of learning style, the
term metacognition has since been expanded to refer to a spectrum
ofmental activities.Metacognitive acts range fromdiscrete processes,
such as thinking about a thought, to more synthetic acts that require
thoughts, feelings, and intentions to be integrated into complex rep-
resentations that later enable individuals to recognize and respond to
life challenges (Lysaker et al., 2013; Semerari et al., 2003). While
metacognition partially overlaps conceptually with neurocognition,
one operational difference between the two is that more synthetic
forms of metacognition are assessed by analyzing discourse and not
by the accuracy of a response to a task. Decrements in metacognition
have been broadly observed in schizophrenia and contribute to func-
tional impairment and decreased quality of life, independent of
neurocognition (Lysaker et al., 2014). Previous studies have linked
different forms of substance use with phenomena related to meta-
cognition such as alexithymia (Saladin et al., 2012) and the ability
to use metacognitive knowledge to respond to challenges (Lysaker
et al., 2014). Chronic cannabis users have shown altered neural net-
works when completing a theory of mind task, similar to those at
risk for the development of psychosis (Roser et al., 2012). It has also
been suggested that persistent cannabis use results in difﬁculty de-
termining and discriminating facial emotions (Bayrakçı et al., 2015).
2. Methods
2.1. Participants
Sixty-six participants (females = 3) with a diagnosis of
schizophrenia (n= 43) or schizoaffective disorder (n= 23), as con-
ﬁrmed by the Structured Clinical Interview for DSM-IV (SCID-I)
(Spitzer et al., 1995), were recruited from the Psychiatry Service of
a VAMedical Center in Indianapolis, Indiana for a larger investigation
on the effects of cognitive remediation on work outcome. Demo-
graphic information can be found in Table 1. During their participa-
tion, participants were being prescribed antipsychotic medication,
receiving outpatient care and were stable as evidenced by no recent
(1month) hospitalizations, or changes in housing ormedication. Par-
ticipants with intellectual disability, deﬁned as a chart diagnosis of
mildmental retardation, or current substance dependence (including
cannabis dependence, but excluding tobacco) were excluded.
2.2. Clinical assessments
Neurocognitionwas indexed via theMATRICS (Measurement and
Treatment Research to Improve Cognition in Schizophrenia) Consen-
sus Cognitive Battery (MCCB), a commonly used index of cognition in
schizophrenia (Nuechterlein et al., 2008). The MCCB assesses speed
of processing, attention, working memory, verbal learning, visualcannabis use mediating cognitive impairment.
Table 1
Demographic information.
Demographic information
Cluster: 1 (n = 34) 2 (n = 10) 3 (n = 22)
Low cannabis/poor cognition Heavy cannabis/moderately impaired cognition Moderate cannabis/higher cognition
Average (SD) Average (SD) Average (SD)
Age 52.53 (10.06) 51.60 (10.76) 45.82 (11.97)
Diagnosis (S/SA) 23/11 8/2 12/10
Gender (m/f) 33 (1) 10/0 20/2
Education (years) 12.29 (2.30) 12.30 (2.45) 13.55 (2.11)
IQ 89.75(15.25) 92.56 (14.08) 98.74 (13.52)
Race (AA/C/H) 14/20/0 4/6/0 10/11/1
Note: SD, standard deviation; S, schizophrenia; SA, schizoaffective disorder; m, male; f, female; IQ, intelligence; AA, African American; C, Caucasian; H, Hispanic.
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total score of the seven domains was used as an overall index of
neurocognitive capacity.
Metacognitive capacity was assessed with the Indiana Psychiatric
Illness Interview (IPII) (Lysaker et al., 2002) and the Metacognitive
Assessment Scale-Abbreviated (MAS-A) (Lysaker et al., 2005; Lysaker
et al., 2014). The IPII is a semi-structured interview that asks subjects
to discuss ﬁve domains, including (1) the story of their life, (2) if they
believe themselves to have a mental illness, and if so, (3) how it may
have affected their life, (4) how their illness controls their life, how
they control their illness, aswell as if their illness is affected by others
and how much others have been affected by their illness, and
(5) what they anticipate to remain the same or be different in the fu-
ture with regard to their interpersonal and psychological experience.
Unique from other psychiatric interviews the IPPI does not inquire
about areas not spontaneously discussed, and thus it provides insight
into synthetic metacognitive capacity. IPII responses were audio re-
corded, and transcribed for further assessment via the MAS-A.
The MAS-A assesses synthetic metacognition in four domains: self-
reﬂectivity, awareness of themindof theother, decentration, andmastery.
The domain of self-reﬂectivity (S) represents an individual's ability to rec-
ognize one's own thoughts and emotions, how these inﬂuence one anoth-
er, and/or how they changeover time. Awareness of themindof the other
(O) represents an individual's capacity to recognize that others have their
own thoughts andemotions. Decentration (D) reﬂects the ability to recog-
nize that events occur of independent motive, outside of the individual.
The domain of mastery (M) measures one's ability to cope with his/her
mental illness. S and M domains are scored between 0 (least) and 9
(max), while O is scored between 0 (least) and 7 (max), and D on a 0
(least) to 3 (max) scale. TotalMAS-A scores can range from0 to 28, indic-
ative of low to high metacognitive capacity, respectively.
Cannabis usewas quantiﬁed through theAddiction Severity Index
(ASI) (McLellan et al., 1980). The ASI asks participants to quantify the
number of months they used cannabis at least three times a week.
Symptoms of psychosis were assessedwith the Positive and Negative
Syndrome Scale (PANSS) (Kay et al., 1987). The PANSS is a semi-
structured interview, scored on a 30-item rating scale between 1
(absence of symptom) to 7 (extreme presence of symptom), and
can be summed into a total score, as well as four subscores including
positive, negative, hostile and cognitive symptoms. An intelligence
quotient (IQ) was also derived with the Wechsler Abbreviated Scale
of Intelligence (WASI) (Wechsler, 1999), which is a measure com-
monly used to assess IQ in both healthy individuals as well as those
with schizophrenia spectrum disorder.
2.3. Procedures
Participants ﬁrst underwent the informed consent process. Then,
participant diagnoses were conﬁrmed by the Structured Clinical In-
terview for the DSM-IV (Spitzer et al., 1995). Eligible participantswere administered the MCCB, IPPI, ASI, and PANSS. After participa-
tion, each IPPI was transcribed and scored using the MAS-A. Raters
on the PANSS and MAS-A were blind to subjects' cannabis use and
neurocognitive performance.
2.4. Statistical analysis
A k-means cluster analysis was used to detect distinct group pro-
ﬁles based on lifetime cannabis use, neurocognitive ability, and
metacognitive capacity. Unlike hierarchical cluster analyses, which
use algorithms for the determination of cluster membership based
on Euclidean distance measures, a k-means cluster analysis has been
selected as this non-hierarchical technique forms clusters of limited
within-cluster variation, compared to between cluster variation, to
generate homogeneous groups (Mooi and Sarstedt, 2011; Norušis,
2012). Further, a k-means cluster analysis is most appropriate in the
presence of existing hypotheses about the number of potential clus-
ters within a sample (Norušis, 2012). Analysis consisted of four
steps. Firstly, indexes of cannabis use (months), neurocognitive ability
(MCCB total score) and metacognitive capacity (MAS-A) were nor-
malized by converting scores into z-scores. Secondly, a k-means clus-
ter analysis was performed to test the hypothesis that subjects could
be differentiated into 3 groups based on little to no, moderate, and
heavy lifetime cannabis use. Both 2 and 4 cluster formations were
assessed to evaluate the validity of the 3 cluster model. Thirdly, ﬁnal
clusters were assessed for group differences in demographic charac-
teristics including gender, diagnosis, age, education, and IQ via a mul-
tivariate general linear model. Fourthly, groups were assessed in the
same manner for differences in symptom proﬁles as indexed by the
total scores and subscores of the MCCB, MAS-A, and PANSS to better
assess areas of each domain that may be suggestive of speciﬁc group
differences. If groups differ in any demographic characteristic(s),
these descriptors were used as co-variates in the multivariate general
linearmodel to evaluate symptom, neurocognition andmetacognitive
proﬁles.
3. Results
The k-means cluster analysis indicated support for a 3-cluster
solution (Fig. 2) based on uneven group membership in both 2- and
4-cluster model analyses. Clusters were labeled based on their clinical
proﬁles: (1) low cannabis/poor cognition (n = 34); (2) heavy
cannabis/moderately impaired cognition (n= 10); and (3) moderate
cannabis/higher cognition (n = 22). A multivariate general linear
model was then used to determine that the clusters were not signiﬁ-
cantly different (p N .05) on the basis of gender, diagnosis, age, educa-
tion, or IQ. Because the groups failed to differ on demographic
characteristics (Table 1), these factors were not included as covariates
in further evaluation.
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Fig. 2. Final clusters from k-means cluster analysis.
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armodel with a factor of group (3: cluster 1, 2, or 3) yielded signiﬁcant
differences (p b .05) in domains of neurocognition, metacognition, and
cannabis use, while demonstrating no group differences on the PANSS
(Table 2). A one-way MANOVA revealed a signiﬁcant multivariate
main effect of group,Wilks'λ=.052, F(46,82)=6.059, pb .001, partial
eta squared=.773, and power to detect the effectwas 1.000. Given the
signiﬁcance of the overall test, between-subject effects were evaluated
for total score and subscores of the MCCB, MAS-A, and cannabis use.
Tests of between-subjects effects indicated signiﬁcant differences
on the MAS total score (F(2,82) = 33.57, p b .001), self-reﬂectivity
(F(2,82) = 21.00, p b .001), other (F(2,82) = 15.30, p b .001),
decentration (F(2,82) = 12.81, p b .001), and mastery (F(2,82) =
21.16, p b .001) (Fig. 3). Post hoc pairwise comparisons with Sidak
correction for multiple comparisons yielded signiﬁcant differencesTable 2
Cluster proﬁles.
Cluster proﬁles
Cluster: 1 (n = 34) 2 (n = 10)
Low cannabis/poor
cognition
Heavy cannabis/moderately impaire
cognition
Average (SD) Average (SD)
Metacognition (MAS-A)
Total 9.07 (2.50) 10.20 (3.20)
Self 3.68 (0.90) 3.90 (1.15)
Other 2.43 (0.63) 2.60 (1.05)
Decentration 0.33 (0.40) 0.30 (0.42)
Mastery 2.66 (1.32) 3.40 (1.51)
Cognition (MCCB)
Total 19.56 (7.05) 29.20 (9.72)
Speed 27.09 (9.66) 35.20 (10.04)
Attention 31.85 (9.23) 35.20 (7.70)
Working
Memory
30.56 (9.76) 37.00 (11.05)
Verbal 32.65 (5.60) 37.90 (11.27)
Visual 29.68 (9.21) 39.20 (12.87)
Reasoning 35.44 (5.19) 39.20 (6.58)
Social Cognition 32.35 (9.89) 37.00 (11.65)
Lifetime cannabis consumption (ASI)
Mean 29.26 (64.93) 397.20 (137.57)
Median .00† 432.0
Symptom proﬁle (PANSS)
Positive 17.24 (5.58) 19.90 (3.90)
Negative 19.71 (5.02) 22.40 (3.27)
Cognitive 17.44 (4.05) 15.80 (3.05)
Hostility 7.65 (3.63) 8.20 (2.90)
Note: SD, standard deviation; MAS-A, Metacognitive Assessment Scale-Abbreviated; MCCB,
nia) Consensus Cognitive Battery (MCCB); ASI, Addiction Severity Index; PANSS, Positive an
† Proportion of zeros was 64.7%.between Clusters 1 and 3 for MAS total score, as well as in subscores
of self, other, decentration, andmastery (p b .001). Post hoc pairwise
comparisons also yielded signiﬁcant differences between clusters 2
and 3 for total score (p b .001), self (p b .001), other (p = .005),
decentration (p= .002), and mastery (p= .007).
Tests of between-subject effects indicated signiﬁcant differences
for MCCB total (F(2,82) = 20.01, p b .001), speed (F(2,82) =10.56,
p b .001), attention (F(2,82) = 7.16, p = .002), working memory
(F(2,82) = 7.76, p= .001), verbal (F(2,82) = 5.58, p= .006), visual
(F(2,82)= 5.50,p= .006), reasoning (F(2,82)= 3.95, p= .024), and
social cognition (F(2,82) = 3.55, p= .034). Post hoc pairwise com-
parisons with Sidak adjustments yielded signiﬁcant differences be-
tween Clusters 1 and 3 for overall (p b .001), speed (p b .001),
attention (p = .001), working memory (p = .001), verbal (p =
.009), visual (p = .028), reasoning (p = .030), and social cognition
(p= .031). Signiﬁcant differences were observed between Clusters
1 and 2 for overall (p= .003) and visual (p= .029) scores. Addition-
ally, Pearson's correlation revealed a signiﬁcant, although small, cor-
relation between the MAS-A total and MCCB overall scores for the
group as a whole (N= 66) (r= .243, p= .049).
Signiﬁcant differences between groups on lifetime cannabis use
were observed (F(2,82)=52.09, p b .001). Post hoc pairwise compar-
isons with Sidak adjustments demonstrated signiﬁcant differences
between Clusters 1 and 2 (p b .001), 1 and 3 (p= .029) and 2 and 3
(p b .001) (Fig. 4).4. Discussion
The potential dose–response relationship between lifetime canna-
bis use and cognition was evaluated, as measured by neurocognitive3 (n = 22)
d Moderate cannabis/higher
cognition
Post hoc comparisons
(p b .05)
Average (SD)
15.11 (2.86) 1 b 3; 2 b 3
5.68 (1.48) 1 b 3; 2 b 3
3.52 (0.73) 1 b 3; 2 b 3
0.93 (0.54) 1 b 3; 2 b 3
4.98 (1.18) 1 b 3; 2 b 3
32.55 (7.96) 1 b 3; 1 b 2
38.64 (8.88) 1 b 3
41.27 (9.44) 1 b 3
39.91 (6.03) 1 b 3
38.32 (5.71) 1 b 3
36.95 (9.57) 1 b 3; 1 b 2
39.91 (7.30) 1 b 3
40.55 (13.18) 1 b 3
102.55 (124.24) 1 b 3; 1 b 2; 2 N 3
30.00
18.32 (4.05)
18.36 (4.69)
15.14 (3.01)
6.68 (2.36)
MATRICS (Measurement and Treatment Research to Improve Cognition in Schizophre-
d Negative Syndrome Scale (PANSS).
Fig. 3.Metacognitive proﬁles of clusters. * = 1 b 3, p b .001; ♦= 2 b 3, p b .001; ◊= 2 b 3, p b. 05.
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sistent with our hypotheses, increased lifetime cannabis use was asso-
ciated with less impairment of neurocognition and metacognition
compared to non-using peers; further, moderate cannabis use was as-
sociatedwith the least cognitive impairment compared to heavy users.
The cluster analysis yielded three homogenous groups: (1) low
cannabis/poor cognition; (2) heavy cannabis/moderately impaired
cognition; and (3) moderate cannabis/higher cognition.
While this analysis was correlational and causality cannot be gar-
nered, there are at least three plausible explanations for our ﬁndings.
Firstly, data suggest that increased cannabis usemay enhance cognition.
Secondly, cannabis may be neuroprotective, thus individuals maintain
cognitive capacity. These notions have been supported by preclinical
(Peres et al., 2016; Zuardi et al., 2012) and human research (Leweke
et al., 2012) investigating cannabidiol (CBD), a secondary chief constitu-
ent of cannabis, as an antipsychotic agent. Signiﬁcantly, while these
studies observed a decrease in positive symptoms of psychosis, evi-
dence is lacking for CBD's effect on cognition. Additionally, if either ex-
planation was true and a dose–response relationship existed, the
highest use cannabis groupwould be expected to have the greatest cog-
nitive ability. This relationship was not observed, however.
A third potential explanation for our ﬁndings generates from the
complex relationship between cannabis use and psychotic experi-
ence. The association between cannabis and the development of psy-
chosis has been observed in epidemiological research (Andréasson
et al., 1987), meta-analyses (Henquet et al., 2005b; Moore et al.,
2007), longitudinal research (Arendt et al., 2005; Niemi-Pynttäri
et al., 2013), and direct Δ-9-THC administration studies (D'Souza
et al., 2004; D'Souza et al., 2005; Morrison et al., 2009). Recently, Di
Forti et al. (2015) have also indicated that cannabis, particularly of
high Δ-9-THC content, uniquely contributed to approximately 24%
of ﬁrst episode psychosis cases in South London between 2005 to
2011, suggesting that cannabis is directly related to the development
of new cases of schizophrenia. Therefore, it is plausible that at least a0
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Fig. 4. Lifetime cannabis use of clusters. 1 b 3 b 2, p b .05.sub-set of individuals in our study with persistent cannabis use may
have developed schizophrenia as a result of their cannabis use. Al-
though speculative, this suggests that these individuals may have
had higher premorbid neurocognitive and metacognitive capacity,
compared to their non-using peers. Previous research supports this
conclusion, ﬁnding that people with schizophrenia who reported
cannabis use had higher premorbid IQ compared to non-using
peers (Ferraro et al., 2013). This notion is also supported by the obser-
vation that bothmoderate and heavy cannabis use groups had signif-
icantly higher social cognition, supporting their ability to both
procure and use cannabis initially, compared to the little to no canna-
bis use group. Additionally, the little to no cannabis use group
showed signiﬁcantly greater neurocognitive impairments compared
to the moderate cannabis use group, in domains of speed, attention,
working memory, verbal, visual, reasoning and social cognition. If
cannabis use increased the vulnerability for the development of psy-
chosis, it is also plausible that continued heavy usemay lead to great-
er neurocognitive and metacognitive deﬁcits, compared to moderate
use. This speculative explanation is also supported by neurobiological
underpinnings of cannabis use and its potential downstream effects
on cognition (Volk and Lewis, 2016).
In addition to these ﬁndings, our study also yielded the unexpect-
ed ﬁnding that the distinct groups failed to differ in severity of psy-
chotic symptoms, suggesting that improved metacognitive ability
may be independent from psychotic symptoms in cannabis-using in-
dividuals with psychosis. Additionally, moderate and heavy cannabis
groups did not differ on neurocognitive ability. Greater group differ-
ences may not have been observed as a rare phenomenon unique to
this sample, or due to the small cluster sizes. Alternatively, the lack
of group differences may be due to a potentially more complex rela-
tionship between metacognition, symptoms of psychosis and canna-
bis use, in that when individuals are categorized based solely on
metacognition groups demonstrate differences in observed
symptomology (Hamm et al., 2012).
To the best of our knowledge, this was one of the ﬁrst studies to
characterize metacognitive ability in schizophrenia spectrum disor-
derwith regard to cannabis use. The literature has found that individ-
uals with schizophrenia spectrum disorder have impaired
metacognitive capacity compared to healthy controls (Hasson-
Ohayon et al., 2015; Ladegaard et al., 2014). Speciﬁcally, our ﬁndings
suggested that individuals with low and heavy cannabis usewere ob-
served to have signiﬁcantly poorer levels of metacognition.Whenwe
examined theMAS-A subscales to understand the clinical meaning of
these deﬁcits,we found that in regard to self-reﬂectivity both low and
heavy cannabis use individuals demonstrated the ability distinguish
between different cognitive operations and could name and partially
distinguish valenced emotions. However, these groupswere general-
ly unable to see fallibility in their thinking. Moderate cannabis use in-
dividuals were able to recognize fallibility of their thoughts, and
partially that their thoughtsmay notmatchwhat is possible in reality.
However, moderate cannabis use individuals were unable to form
20 A.M. Schnakenberg Martin et al. / Schizophrenia Research: Cognition 6 (2016) 15–21integrated depictions of themselves with understanding of how their
thoughts and feelings were connected. Regarding the awareness of
others' minds, both low and heavy cannabis use individuals were
also able to recognize that others have autonomousmental activities,
but were unable to distinguish different cognitive operations of
others, as the moderate use group was able to do. Additionally, the
moderate use group was also able to partially name and distinguish
different emotions in others; however, these individuals were gener-
ally unable to discern others' intentions, and could not integrate
thoughts, intentions and feelings of another. Regarding decentration,
moderate cannabis users were also able recognize more often that
they are not the center of others' mental activities, compared to
both low and heavy cannabis using individuals who could not.
Moderate users were, however, unable to acknowledge that
others may perceive an event in a valid, although different way
from their own. Finally, in regard to mastery, the moderate use
group showed the highest level of mastery, demonstrating the
ability to respond to their psychological problem by adjusting
their behavior, although unable to change how they think about
the problem. The low use group demonstrated occasional gross
avoidance of their psychological problem, while the heavy use
group was able to reach out for support, but showed only partial
ability to change their behavior.
There are several limitations that should be addressed. The sample
was largely male, with unbalanced and relatively small groups
(e.g., n=10 in cluster 2 ofmoderate users). Subjects with current sub-
stance dependence were also excluded. Replication is needed with a
larger and broader sample, including women, individuals who are
not currently undergoing treatment, and those actively meeting
criteria for cannabis dependence. Also, the initiation of cannabis and
psychotic symptoms are unknown. Importantly, it is also unclear
if these neurocognitive and metacognitive proﬁles predate the
onset of cannabis use, or are a result of use. The role of cognitive
reserve was also not assessed, which will be important for future
research. The results of this study may also not generalize to
non-treatment seeking individuals, or those unwilling to partici-
pate in research. Finally, the content of the cannabis used by par-
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